Welcome to our dedicated page for Castle Biosciences news (Ticker: CSTL), a resource for investors and traders seeking the latest updates and insights on Castle Biosciences stock.
Castle Biosciences, Inc. (symbol: CSTL) is a pioneering company specializing in diagnostic tests for a variety of cancers. Founded in 2008, Castle Biosciences has dedicated itself to advancing cancer care through objective and accurate testing. The company's primary mission is to provide physicians and patients with personalized, clinically actionable genomic information to facilitate more precise treatment decisions.
Castle Biosciences offers a range of diagnostic tests that assist doctors in the treatment of various cancers. Their current product portfolio includes tests for cutaneous melanoma, uveal melanoma, esophageal adenocarcinoma, mesothelioma, and glioma. Notably, their products include DecisionDx-Melanoma, DecisionDx-CMSeq, and DecisionDx-PRAME, all designed to provide vital information that can influence the course of cancer treatment.
The company is not just limited to its existing portfolio; it actively engages in research programs aimed at developing diagnostic tests for other under-served cancers, such as rectal cancer and soft tissue sarcoma. These initiatives underscore Castle Biosciences' commitment to addressing gaps in cancer diagnostics and improving patient outcomes.
Castle Biosciences collaborates closely with leading members of the oncology community to ensure that their tests are both innovative and clinically relevant. This collaboration spans the discovery, development, and practical utilization of their diagnostic tests, reinforcing their standing as a crucial player in the field of cancer diagnostics.
The company is currently in a robust financial condition, reflecting its successful commercialization efforts and consistent revenue growth. Recent achievements include expanding their test portfolio and forging strategic partnerships aimed at broadening their market reach and enhancing their technological capabilities.
For the latest updates and detailed information on Castle Biosciences, Inc. and its products, please visit their official website at www.castlebiosciences.com.
Castle Biosciences will present new data on its TissueCypher Barrett's Esophagus test at the American Foregut Society 2024 Annual Meeting. The data demonstrates the test's ability to independently predict the risk of esophageal cancer progression in patients with Barrett's esophagus (BE).
Key findings include:
- TissueCypher alone is the strongest predictor of progression to esophageal cancer, outperforming combinations with clinicopathologic risk factors.
- For non-dysplastic BE patients, TissueCypher was the only significant predictor of progression.
- The test guided risk-aligned management decisions in 86% of patients, leading to upstaged management in 21% and supporting long-interval surveillance in 90% of low-risk patients.
These results highlight TissueCypher's clinical value in identifying high-risk patients and tailoring treatment plans based on cancer progression likelihood.
Castle Biosciences (Nasdaq: CSTL) announced that its Chief Operating Officer, Kristen Oelschlager, has been named the 2024 Jon W. McGarity Arizona Bioscience Leader of the Year by the Arizona Bioindustry Association (AZBio). Oelschlager, a registered nurse with over 15 years of experience in clinical nursing, operations services, and research, is recognized for her significant contributions to the progression of the bioscience industry in Arizona.
As a co-founder of Castle Biosciences in 2008, Oelschlager has played a important role in the company's growth and success. Castle Biosciences specializes in innovative testing solutions to guide treatment decisions for cancer patients. The award will be presented at the AZBio Awards on September 18, 2024, at the Phoenix Convention Center.
Castle Biosciences (Nasdaq: CSTL) has published a new study in the World Journal of Surgical Oncology, demonstrating the effectiveness of their DecisionDx-Melanoma test in predicting sentinel lymph node (SLN) positivity risk. The study shows that the test can help reduce unnecessary sentinel lymph node biopsy (SLNB) surgeries by 33% in patients with T1-T2 melanoma tumors.
Key findings include:
- None of the patients classified as low-risk by DecisionDx-Melanoma had a positive SLN
- 31.9% SLN positivity rate in patients predicted to have >10% risk
- Potential SLNB reduction rate of 33% in patients with AJCC8 T1-T2 tumors
The study suggests that DecisionDx-Melanoma can improve patient selection for SLNB procedures, potentially reducing healthcare costs and unnecessary surgeries while maintaining good patient outcomes.
Castle Biosciences (Nasdaq: CSTL) has published a new study in Future Oncology validating the use of its DecisionDx-SCC test for guiding adjuvant radiation therapy (ART) decisions in high-risk cutaneous squamous cell carcinoma (SCC) patients. The study, involving 399 patients and 423 tumors, showed that:
1. Patients with Class 2B results (highest metastatic risk) treated with ART had a 50% decrease in metastatic disease progression.
2. Patients with Class 1 results (lowest metastatic risk) showed no difference in disease progression with or without ART, suggesting they may defer treatment.
3. Class 2A patients showed no significant benefit from ART despite intermediate risk levels.
This study corroborates findings from a recent 2024 study, further supporting DecisionDx-SCC's ability to improve risk-aligned patient care through precise, tumor-biology-based risk stratification.
Castle Biosciences (Nasdaq: CSTL), a company specializing in innovative health tests, has announced its participation in two upcoming investor conferences. The company's executive management will present a company overview at Baird's 2024 Global Healthcare Conference on September 11, 2024, at 9:05 a.m. Eastern time. A live audio webcast of this presentation will be available on Castle Biosciences' website, with a replay accessible afterwards.
Additionally, Castle Biosciences will be available for one-on-one investor meetings during the 8th Annual Lake Street Best Ideas Growth (BIG8) Conference on September 12, 2024. Interested parties can request meetings exclusively through Lake Street Capital Markets. These conferences provide opportunities for investors to gain insights into Castle Biosciences' operations and future plans.
Castle Biosciences (NASDAQ: CSTL) reported strong Q2 2024 results, with revenue increasing 74% to $87 million and total test reports up 49% year-over-year. The company raised its full-year 2024 revenue guidance to $275-300 million from $255-265 million. Key highlights include:
- Delivered 25,102 total test reports, up 49% from Q2 2023
- Gross margin improved to 81% from 74% in Q2 2023
- Net income of $8.9 million, compared to a net loss of $18.8 million in Q2 2023
- Adjusted EBITDA of $21.5 million, up from -$5.3 million in Q2 2023
- Cash, cash equivalents, and marketable securities totaled $259.7 million
The company highlighted positive developments for its DecisionDx-SCC and TissueCypher tests, including new clinical data and guideline recognition.
Castle Biosciences (Nasdaq: CSTL), a company specializing in innovative health tests for patient care, has announced its participation in the Canaccord Genuity 44th Annual Growth Conference. The company's executive management is scheduled to present a company overview on Tuesday, Aug. 13, 2024, at 12:30 p.m. Eastern time.
Investors and interested parties can access a live audio webcast of the presentation through Castle Biosciences' website at ir.castlebiosciences.com/events-presentations/. For those unable to attend the live event, a replay of the webcast will be made available after the presentation concludes.
Castle Biosciences (Nasdaq: CSTL) has partnered with Teddi Mellencamp Arroyave, a stage II melanoma survivor, to launch a campaign raising awareness about melanoma prevention, detection, and management. Mellencamp Arroyave will share her personal journey with melanoma on Instagram, alongside discussions with Dr. Aaron S. Farberg and melanoma survivor Morgan England.
The campaign aims to educate the public about melanoma, the deadliest form of skin cancer, which claims nearly 20 American lives daily. Castle's DecisionDx®-Melanoma test provides personalized information about a patient's risk of melanoma recurrence, metastasis, and sentinel lymph node positivity, helping guide treatment decisions and improve patient survival.
Castle Biosciences (Nasdaq: CSTL) has announced the release of its financial results for Q2 and H1 2024 on Monday, Aug. 5, 2024, after market close. The company, which specializes in innovative health tests for patient care, will host a conference call and webcast at 4:30 p.m. Eastern time on the same day to discuss the results.
Investors can access the live webcast through the provided link or via the company's Investor Relations page. For those joining by phone, the U.S. dial-in number is 1 833 470 1428, with international numbers available. The access code for both is 802518. A Q&A session will follow management's commentary, and a replay of the webcast will be available after the call.
Castle Biosciences (Nasdaq: CSTL) has been recognized with several prestigious awards through the 2024 Top Workplaces program. The company earned its third consecutive Arizona Top Workplaces award from AZ Central, a second consecutive national Healthcare Industry Top Workplace award, and five Top Workplaces Culture Excellence Awards for Innovation, Work-Life Flexibility, Compensation & Benefits, Leadership, and Purpose & Values. These accolades are based on anonymous employee feedback collected via a third-party survey by Energage, emphasizing Castle's commitment to a positive workplace culture.
CEO Derek Maetzold expressed pride in the repeated recognition, attributing it to the company's dedication to fostering an exceptional, people-first environment that promotes employee growth and patient care. The Top Workplaces program, now in its 17th year, evaluates companies based on 15 culture drivers, including alignment, execution, and connection.
FAQ
What is the current stock price of Castle Biosciences (CSTL)?
What is the market cap of Castle Biosciences (CSTL)?
What does Castle Biosciences specialize in?
When was Castle Biosciences founded?
What types of cancer does Castle Biosciences have tests for?
What are some of Castle Biosciences' notable products?
Is Castle Biosciences involved in research for new diagnostic tests?
Where can I find more information about Castle Biosciences and its products?
What is the primary mission of Castle Biosciences?
Does Castle Biosciences collaborate with other entities?
What is Castle Biosciences' financial condition?
How does Castle Biosciences contribute to cancer care?
